BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nishiofuku H, Tanaka T, Aramaki T, Boku N, Inaba Y, Sato Y, Matsuoka M, Otsuji T, Arai Y, Kichikawa K. Hepatic arterial infusion of 5-fluorouracil for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy: a multicenter, retrospective analysis. Clin Colorectal Cancer. 2010;9:305-310. [PMID: 21208845 DOI: 10.3816/ccc.2010.n.044] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Fiorentini G, Carandina R, Sarti D, Nardella M, Zoras O, Guadagni S, Inchingolo R, Nestola M, Felicioli A, Barnes Navarro D, Munos Gomez F, Aliberti C. Polyethylene glycol microspheres loaded with irinotecan for arterially directed embolic therapy of metastatic liver cancer. World J Gastrointest Oncol 2017; 9(9): 379-384 [PMID: 28979720 DOI: 10.4251/wjgo.v9.i9.379] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
2 Zacharias AJ, Jayakrishnan TT, Rajeev R, Rilling WS, Thomas JP, George B, Johnston FM, Gamblin TC, Turaga KK. Comparative Effectiveness of Hepatic Artery Based Therapies for Unresectable Colorectal Liver Metastases: A Meta-Analysis. PLoS One. 2015;10:e0139940. [PMID: 26448327 DOI: 10.1371/journal.pone.0139940] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
3 Qiang WG, Shi LR, Li XD, Wu QQ, Zhao JM, Chen LJ, Yang Y, Wu J, Ji M, Wu CP. Hepatic arterial infusion plus systemic chemotherapy as third-line or later treatment in colorectal liver metastases. Clin Transl Oncol 2015;17:870-5. [PMID: 26055340 DOI: 10.1007/s12094-015-1317-8] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 Qingwei Z, Dongsheng H, Duo L, Youlei W, Songxia Y, Ziqi Y, Lanjuan L. Fluorouracil Supplemented With Oxaliplatin or Irinotecan for Solid Tumors: Indications From Clinical Characteristics and Health Outcomes of Patients. Front Oncol 2020;10:1542. [PMID: 32984012 DOI: 10.3389/fonc.2020.01542] [Reference Citation Analysis]